TherapeuticsMD (TXMD) Getting Somewhat Positive Press Coverage, Study Shows

Media coverage about TherapeuticsMD (NASDAQ:TXMD) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.797326308532 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

Shares of TherapeuticsMD (NASDAQ:TXMD) opened at $6.15 on Friday. The company has a market cap of $1,350.34, a P/E ratio of -15.37 and a beta of 1.36. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. The business had revenue of $4.42 million for the quarter, compared to analyst estimates of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company’s quarterly revenue was down 19.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.13) earnings per share. research analysts expect that TherapeuticsMD will post -0.37 EPS for the current fiscal year.

Several research analysts have weighed in on TXMD shares. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday, December 20th. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Deutsche Bank set a $9.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Cantor Fitzgerald restated a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a research report on Wednesday, November 29th. Finally, Jefferies Group restated a “buy” rating and set a $15.00 target price on shares of TherapeuticsMD in a research report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $14.50.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the stock in a transaction dated Friday, December 8th. The shares were acquired at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the transaction, the director now directly owns 3,555 shares of the company’s stock, valued at $22,076.55. The purchase was disclosed in a filing with the SEC, which is available at this link. 23.92% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-therapeuticsmd-txmd-share-price.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply